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Abstract. Melatonin exerts oncostatic activity in breast cancer 
through antiangiogenic actions. There, the aim of the present 
study was to ascertain whether melatonin modulates, in a coor-
dinated action, angiopoietin-1 (ANG-1), ANG-2, their cognate 
Tie2 receptor and VEGF in co-cultures of human endothelial 
cells (HUVECs) and breast cancer (MCF-7) cells. To accom-
plish this we used co-cultures of human breast cancer cells 
(MCF-7) or non-malignant human mammary epithelial cells 
(MCF-10A) with endothelial cells (HUVECs). The presence 
of breast cancer cells increased HUVEC proliferation and 
1 mM melatonin prevented this effect. ANG-1, ANG-2 and 
VEGF levels in co-culture media and mRNA expression were 
upregulated and Tie2 mRNA expression was downregulated in 
the HUVECs and MCF-7. Melatonin (1 mM) downregulated 
ANG-1, ANG-2 and VEGF levels in the co-culture media 
and mRNA expression in both types of cells and upregulated 
Tie2 mRNA expression in HUVECs. ANG-1, ANG-2, Tie2 
and VEGF mRNA expression were not modified during 
HUVEC/MCF-10A co-culture. Estradiol (10 nM) increased 
ANG-1, ANG-2 and VEGF mRNA expression in HUVECs 
and melatonin (1 mM) counteracted this effect. We conclude 
that melatonin simultaneously coordinates downregulation of 
angiopoietins with a reduction in VEGF, which could be an 
effective therapeutic strategy for blocking tumor angiogenesis.
Introduction
The formation of new blood vessels from the existing vascu-
lature is essential to support tumoral development (1). Since 
neo-angiogenesis is a key event in tumor progression, anti-
angiogenic agents are considered as an alternative strategy 
in cancer treatment (2). In healthy tissues, the balance of 
angiogenic activating and inhibiting factors determines the 
transition of endothelial cells between a pro-angiogenic or a 
quiescent stage (2). Vascular endothelial growth factor (VEGF) 
and angiopoietins are some of the main pro-angiogenic 
factors (3,4). VEGF is one of the most important molecules 
stimulating tumoral angiogenesis and an increased VEGF 
expression has been described in different types of cancers, 
such as breast, brain, lung, urothelial and gastrointestinal tract 
tumors (5). In mammary tumors, VEGF is released by human 
breast cancer cells and binds VEGF receptors triggering 
proliferation, growth, survival and migration of endothelial 
cells (6-8). Angiopoietins are endothelial-produced proteins 
which bind the tyrosine kinase receptor Tie2, modulating 
vessel stability (9). Although four angiopoietins (ANG-1 
to ANG-4) have been described, ANG-1 and ANG-2 are 
the most widely studied. ANG-1 is a Tie2 receptor agonist 
expressed in vascular mural cells and non-vascular normal and 
tumor cells. It is a vascular stabilizing factor that stimulates 
recruitment of pericytes and smooth muscle cells, collaborates 
to maintain vascular integrity and quiescence and is also able 
to promote angiogenesis (9,10). Contrary to ANG-1, ANG-2 
behaves as an antagonist of Tie2, blocking ANG-1-mediated 
phosphorylation of Tie2 therefore reducing the interactions 
between endothelial and perivascular support cells and extra-
cellular matrix, decreasing vascular integrity and causing 
vessel regression in the absence of angiogenic factors, whereas 
it potentiates angiogenesis in the presence of VEGF (9,11). 
ANG-2 is mainly produced by endothelial cells and formed 
during vascular remodelling (11). A wide number of malig-
nant tumors show upregulation of both ANG-1 and ANG-2 
angiopoietins, promoting a shift in the ANG-1:ANG-2 ratio 
towards ANG-2 which in the presence of VEGF is associated 
with tumor angiogenesis (12). Tie2 receptors bind directly to 
angiopoietins, have strong tyrosine kinase activity, and are 
selectively expressed in endothelial cells, although other cell 
types including early hematopoietic cells and subsets of mono-
cytes also express Tie2 (13). Angiogenesis is dependent on a 
dynamic equilibrium between the production of VEGF and 
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angiopoietins that must be both quantitatively and temporally 
coordinated (14).
Melatonin, synthesized and released from the pineal gland, 
has been demonstrated to have oncostatic actions in hormone-
dependent tumors (15-17). Melatonin exerts oncostatic 
activity through several biological mechanisms including: 
indirect effects of melatonin via the hypothalamic-pituitary-
reproductive axis, which results in the downregulation of 
some of the hormones that may stimulate proliferation of 
malignant cells, such as estrogenic compounds produced 
by the gonads (18); direct antiestrogenic molecular mecha-
nisms that take place inside epithelial cells of the mammary 
tissue (19,20); antioxidant effects (21); melatonin has been 
also implicated in both hemopoiesis and enhancement of 
anticancer immunity (22); inhibition of telomerase in epithe-
lial malignant cells (23,24); inhibition of fatty acid uptake 
and fat metabolic pathways (25,26) and inhibition of angio-
genesis (27-29). With respect to its antiangiogenic effects, 
in co-cultures of human breast cancer and endothelial cells, 
melatonin was found to regulate the tumor microenvironment 
through the downregulation of VEGF expression in human 
breast cancer cells, which results in a decrease of the secretion 
of VEGF and as a consequence, a reduction in the levels of 
VEGF around endothelial cells (28-30). Melatonin strongly 
inhibits the proliferation as well as the invasion/migration of 
endothelial cells, disrupts tube formation and counteracts the 
VEGF-stimulated tubular network assembly (29). Melatonin 
also shows indirect antiangiogenic effects by inhibiting 
various other tumor growth factors, such as IGF, EGF and 
ET-1, which are strong mitogens and stimulators of cancer 
angiogenesis (31). Neutralization of reactive oxygen species 
which, during hypoxia, plays an important role in stabilizing 
hypoxia-inducible factor HIF-α (32) is another indirect antian-
giogenic effect of melatonin.
Although a variety of factors can modulate endothelial cell 
response, a complementary and coordinated action of VEGF 
and angiopoietins during angiogenesis is required (9,33). 
Since melatonin can modulate VEGF in tumor cells and has 
antiangiogenic effects, in the present study, we aimed to ascer-
tain whether melatonin modulates in a coordinated action 
angiopoietins 1 and 2, their cognate Tie2 receptor and VEGF 
in vitro in endothelial cell cultures. To accomplish this we 
used co-cultures of human breast cancer cells (MCF-7) with 
human umbilical vein endothelial cells (HUVECs).
Materials and methods
Cells and culture conditions. Human umbilical vein endothe-
lial cells (HUVECs) were purchased from the American Type 
Culture Collection (ATCC; Rockville, Md, USA). They were 
maintained as monolayer cultures in 58.1 cm2 plastic culture 
plates in Vascular Cell Basal Medium (VCBM) (ATCC) supple-
mented with Endothelial Cell Growth Kit-BBE (ATCC) which 
consisted of 2% fetal bovine serum (FBS; PAA Laboratories, 
Pasching, Austria), 0.2% bovine brain extract, 5 ng/ml rhEGF, 
10 mM L-glutamine, 0.75 U/ml heparin sulfate, 1 µg/ml 
hydrocortisone hemisuccinate, 50 µg/ml ascorbic acid, peni-
cillin (20 U/ml) and streptomycin (20 µg/ml) (Sigma-Aldrich, 
Madrid, Spain) at 37̊C in a humid atmosphere containing 5% 
CO2. To avoid genetic mutation and low viability, no more than 
six passages of HUVECs were used for the following experi-
ments.
MCF-7 human breast cancer cells were purchased from 
ATTC. They were maintained as monolayer cultures in 
58.1 cm2 plastic culture plates in Dulbecco's modified Eagle's 
medium (dMEM) (Sigma-Aldrich) supplemented with 10% 
FBS, penicillin (20 U/ml) and streptomycin (20 µg/ml) at 37̊C 
in a humid atmosphere containing 5% CO2.
Non-malignant human mammary epithelial cell line 
(MCF-10A) was purchased from ATTC. They were main-
tained as monolayer cultures in 58.1 cm2 plastic culture plates 
in dMEM/F12 supplemented with 5% horse serum, 0.5 µg/ml 
hydrocortisone (all from Sigma-Aldrich), 20 ng/ml epidermal 
growth factor (R&d Systems Europe Ltd., Abingdon, 
UK), 100 ng/ml cholera toxin, 10 µg/ml insulin (both from 
Sigma-Aldrich), penicillin (20 U/ml) and streptomycin 
(20 µg/ml) at 37̊C in a humid atmosphere containing 5% CO2.
Co-culture of HUVECs and MCF-7 or MCF-10A cells. 
HUVECs were co-cultured together with MCF-7 or MCF-10A 
cells using Falcon 6-multiwell plates and Falcon cell culture 
inserts. HUVECs were plated (50x104 cells/well) on the 
bottom wells in VCBM supplemented with 2% FBS and incu-
bated overnight. At this time, MCF-7 cells (40x104 cells) or 
MCF-10A cells (30x104 cells) were seeded on the permeable 
membrane (0.45-µm) of the tissue-culture inserts in dMEM 
supplemented with 10% FBS for 24 h. HUVECs and MCF-7 or 
MCF-10A cells were cultured separately for 24 h to establish 
attachment. After 24 h, MCF-7 or MCF-10A seeded inserts 
were moved over the HUVEC cell cultures in the 6-well 
plates in fresh VCBM supplemented with 2% FBS to create 
the hanging co-culture setup (Fig. 1). due to the membrane 
pore size and diffusional distance between cells within this 
setup, cell to cell contact is prevented but paracrine signalling 
can occur between endothelial cells in the 6-well plate and 
epithelial cells on the insert. After 24 h, media were replaced 
with VCBM supplemented with 2% FBS containing melatonin 
(1 mM or 1 nM) or vehicle (ethanol) for 4 h to measure mRNA 
expression of angiogenic factors or for 72 h to measure prolif-
eration and ANG-1, ANG-2 and VEGF protein levels. At the 
Figure 1. Schematic representation of the Falcon 6-multiwell plates and 
Falcon cell culture inserts used in the co-cultures. In some experiments 
HUVECs were seeded in the lower compartment and MCF-7 or MCF-10A 
cells in the upper compartment. In other experiments, the cells were 
exchanged with HUVECs at the top and MCF-7 or MCF-10A in the bottom.
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end of the experiment, media were collected, centrifuged to 
remove particulates and subjected to measurement of ANG-1, 
ANG-2 and VEGF protein levels. Cells (HUVECs) in the 
bottom plate were evaluated for proliferative indices by the 
MTT method and for ANG-1, ANG-2, Tie2 and VEGF mRNA 
expression by RT-PCR. Since we were only able to measure 
ANG-1, ANG-2, Tie2 and VEGF mRNA expression of the 
cells that were in the lower compartment, in other experiments 
MCF-7 cells were plated (80x104 cells/well) on the bottom 
wells and HUVECs (30x104) on the permeable membrane 
of the tissue-culture inserts to be able to measure ANG-1, 
ANG-2, Tie2 and VEGF mRNA expression by RT-PCR in 
MCF-7 cells.
Measurement of cellular proliferation. Since the reduction of 
tetrazolium salts is widely accepted as a reliable way to examine 
cell proliferation, we used the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) method (34), reading 
absorbance at 570 nm in a microplate reader (Multiskan 
RC 351; LabSystems Vienna, VA, USA). MTT was obtained 
from Molecular Probes Inc. (Eugene, OR, USA).
Measurement of ANG-1, ANG-2, Tie2 and VEGF mRNA 
expression. Analysis of the ANG-1, ANG-2, Tie2 and VEGF 
mRNA expression in HUVECs, MCF-7 and MCF-10A cells 
was carried out by real-time reverse transcription RT-PCR 
after incubation of cells with either 1 mM melatonin and/or 
estradiol 10 nM (Sigma-Aldrich) and/or vehicle (ethanol) for 
4 h. The total cellular RNA was isolated from HUVECs or 
MCF-7 cells and purified using the NucleoSpin RNA II kit 
(Machenery-Nagel, düren, Germany) following the 
manufacturer's instructions. Integrity of RNA was assessed by 
electrophoresis in ethidium bromide-stained 1% agarose- 
Tris-borate EdTA gels. The absorbance ratio A260 nm/A280 nm 
was >1.8. For cdNA synthesis, 0.5 µg of total RNA was 
denatured at 65̊C for 10 min and reverse transcribed for 
50 min at 45̊C with a cDNA synthesis kit (BioLine, London, 
UK) in a final volume of 20 µl in the presence of 500 ng of 
oligo(dT)12-18 primers. Quantitative real-time PCRs were 
performed using the following set of human ANG-1-specific 
primers: [5'-GAAGGGAACCGAGCCTATTC-3' (forward) 
and 5'-AGGGCACATTTGCACATACA-3' (reverse)]; ANG-2-
specific primers [5'-AAGAGAAAGATCAGCTACAGG-3' 
(forward) and 5'-CCTTAGAGTTTGATGTGGAC-3' (reverse)], 
Tie-2-specific primers [5'-AAGACCTACGTGAATACCAC-3' 
(forward) and 5'-GAAACAGAGGGTATACAGATG-3' 
(reverse)]; and human VEGF 165-specific primers [5'-ACC 
AAGGCCAGCACATAGG-3' (forward) and 5'-ACGCTC 
CAGGACTTATACCG-3' (reverse)] (Sigma Genosys Ltd., 
Cambridge, UK). As a control quantification, s14 mRNA was 
also subjected to real-time RT-PCR using a set of specific 
primers [5'-TCCTGCGAGTGCTGTCAGAG -3' (forward) and 
5'-TCACCGCCCTACACATCAAA-3' (reverse)] (Sigma 
Genosys Ltd.). RT-PCRs were performed in a MX3005P 
system (Stratagene, La Jolla, CA, USA) using Brilliant® 
SYBR®-Green PCR Master Mix (Applied Biosystems, Madrid, 
Spain) following the manufacturer's instructions. Amplifi-
cations were performed for 40 cycles using the following 
temperature profile: 60̊C, 45 sec (annealing); 72̊C, 30 sec 
(extension) and 95̊C, 30 sec (denaturation). Each reaction was 
run 9-fold by quadruplicate. Melting curves were performed to 
verify that only a single product with no primer-dimers was 
amplified. For the primers used there were no differences 
between transcription efficiencies, and the fold-change in each 
sample was calculated by the 2-ΔΔCt method (35).
Measurement of ANG-1, ANG-2 and VEGF protein levels. In 
order to measure ANG-1, ANG-2 and VEGF protein levels 
in cell co-culture media, samples were collected, centrifuged 
and processed immediately. For the determination of VEGF 
concentration in the HUVEC/MCF-7 cell co-culture media 
a human VEGF Immunoassay kit (R&d Systems Europe 
Ltd.) was used. The samples (in triplicate) were processed 
according to the supplier's instructions. At the end of the 
procedure, absorbance was determined at a wavelength of 
450 nm, with corrections at 540 nm. For the determination 
of ANG-1 and ANG-2 concentration in the HUVEC/MCF-7 
cell co-culture media we used a Human Angiopoietin-1 or -2 
Immunoassay kit (R&d Systems Europe Ltd.) following the 
supplier's instructions.
Statistical analysis. data are expressed as the mean ± stan-
dard errors of the mean (SEM). Statistical differences between 
groups were analyzed using one way analysis of variance 
(ANOVA), followed by the Student-Newman-Keuls test. 
Results were considered as statistically significant at P<0.05.
Results
Melatonin counteracts the stimulatory effect on HUVEC 
proliferation induced by the presence of tumoral cells. Since 
reciprocal growth factor exchange between endothelial and 
breast cancer cells within the tumor microenvironment may 
directly stimulate neovascularization, we firstly employed 
co-cultures of HUVECs (lower compartment of the chamber) 
and MCF-7 (upper compartment of the chamber) cells to 
investigate whether the presence of malignant epithelial 
cells affects the growth of the endothelial cells. Indeed, we 
observed that the presence of breast cancer cells promoted 
an increase in HUVEC proliferation (P<0.01) and 1 mM 
melatonin prevented this stimulatory effect (Fig. 2A). Since 
melatonin at physiological concentrations did not affect cell 
proliferation of endothelial cells, we used 1 mM concentration 
of melatonin in the following experiments. The presence of 
non-malignant breast epithelial cells in the co-cultures did not 
promote an increase in HUVEC proliferation and melatonin 
had no effect (Fig. 2B).
Effects of melatonin on protein levels of angiogenic factors. 
With the aim of determining whether the increase in HUVEC 
proliferation could be due to the release of angiogenic factors, 
such as ANG-1, ANG-2 and VEGF, we measured ANG-1, 
ANG-2 and VEGF concentrations in the cell co-culture media. 
The presence of breast cancer cells in the upper compartment 
of the chamber significantly increased the concentrations 
of ANG-1, ANG-2 and VEGF (P<0.001) in the co-culture 
media, whereas the addition of 1 mM melatonin decreased the 
concentration of ANG-1, ANG-2 and VEGF and counteracted 
the stimulatory effect induced by the presence of tumoral cells 
(P<0.001) (Fig. 3).
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Effects of melatonin on mRNA expression of angiogenic 
factors. With the aim of determining whether this inhibitory 
effect of melatonin on ANG-1, ANG-2 and VEGF production 
was due to a downregulation of ANG-1, ANG-2 and VEGF 
mRNA expression, total RNA was isolated. RT-PCR was 
performed using specific primers for human ANG-1, 
ANG-2 and VEGF and gene s14 as housekeeping. mRNA 
expression of angiogenic factors in endothelial cells was 
significantly influenced by co-culture with human breast 
cancer cells (Fig. 4). ANG-1, ANG-2 and VEGF mRNA 
expression was significantly (P<0.001) upregulated during 
the HUVEC/MCF-7 co-culture relative to the HUVEC 
monoculture. The addition of melatonin (1 mM) to the 
co-culture downregulated ANG-1, ANG-2 and VEGF mRNA 
expression in endothelial cells, showing a 30% reduction in 
ANG-1, 50% downregulation in ANG-2 and 70% reduction 
in VEGF mRNA expression (Fig. 4). Melatonin induced a 
higher decrease in ANG-2 than ANG-1 and shifted ANG-1/
ANG-2 balance in favor of ANG-1. The presence of breast 
cancer cells also decreased Tie2 mRNA expression, the 
specific tyrosine kinase receptor Tie2 of ANG-1 and ANG-2 
in endothelial cells. This effect was significantly counteracted 
by the addition of 1 mM melatonin (Fig. 4).
Significant upregulation of ANG-1, ANG-2 and 
VEGF mRNA expression occurred also in MCF-7 cells 
during co-culture with endothelial cells relative to MCF-7 
monoculture (Fig. 5). The addition of melatonin 1 mM to the 
co-culture significantly (P<0.001) downregulated ANG-1, 
ANG-2 and VEGF mRNA expression and upregulated Tie2 
mRNA expression in breast cancer cells (Fig. 5).
The expression of the angiogenic factors in endothelial 
cells, in the presence of non-malignant MCF-10A breast 
epithelial cell line was also assessed. ANG-1, ANG-2, Tie2 and 
VEGF mRNA expression levels were not modified during the 
HUVEC/MCF-10A co-culture in comparison to the HUVEC 
monoculture (Fig. 6). The addition of melatonin (1 mM) to the 
co-culture only upregulated ANG-2 mRNA expression in the 
endothelial cells (Fig. 6).
Figure 3. Effects of melatonin (1 mM) on ANG-1, ANG-2 and VEGF protein levels in media of co-cultures of HUVECs and MCF-7 cells determined by 
ELISA immunoassay kits. HUVECs were plated (50x104/well) on the bottom wells in VCBM supplemented with 2% FBS and incubated overnight. Then, 
MCF-7 (40x104) cells were seeded on the permeable membrane (0.45 µm) of the tissue-culture inserts in dMEM supplemented with 10% FBS for 24 h. Media 
were then replaced with VCBM supplemented with 2% FBS containing melatonin (1 mM) or vehicle (ethanol) for 72 h. At the end of the experiment, media 
were collected, centrifuged to remove particulates and subjected to measurement of ANG-1, ANG-2 and VEGF protein levels. data are expressed as the 
percentage of the control group, cultures of only HUVECs (mean ± SEM). aP<0.001 vs. HUVEC; bP<0.001 vs. HUVEC + MCF-7.
Figure 2. Effects of melatonin (1 mM and 1 nM) on proliferation of HUVECs, in the presence of (A) breast cancer cells (MCF-7) or (B) non-malignant human 
mammary epithelial cell line (MCF-10A) in the culture. HUVECs were plated (50x104 cells/well) on the bottom wells in VCBM supplemented with 2% FBS 
and incubated overnight. Then, MCF-7 (40x104) or MCF-10A (30x104) cells were seeded on the permeable membrane (0.45 µm) of the tissue-culture inserts 
in dMEM supplemented with 10% FBS for 24 h. Media were then replaced with VCBM supplemented with 2% FBS containing melatonin (1 mM or 1 nM) or 
vehicle (ethanol) for 72 h. At the end of the experiment, cell proliferation was measured by the MTT method. data are expressed as the percentage of the control 
group, cultures of only HUVECs (mean ± SEM). aP<0.05 vs. HUVEC; bP<0.001 vs. HUVEC + MCF-7; cP<0.001 vs. HUVEC + MCF-7 + melatonin 1 mM.
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Estradiol (10 nM), added to both compartments of the 
multi-well plate, increased ANG-1, ANG-2 and VEGF mRNA 
expression in HUVECs and melatonin (1 mM) significantly 
(P<0.001) counteracted this effect (Fig. 7).
Discussion
Tumor vascular neo-angiogenesis is an intrincate dynamic 
process that has an important role in tumor ontogenesis and 
progression. The VEGF pathway and more recently, ANG/Tie2 
receptor signaling are considered the main regulators of 
different mechanisms of tumor vascularization (4,9-12). VEGF 
synthesized in and secreted by cancer cells, plays a crucial role 
in the progression and development of malignant mammary 
tumors since VEGF stimulates vascular permeability and 
proliferation of endothelial cells from contiguous blood 
vessels (36). Angiopoietin-1 (ANG-1) maintains the integrity 
of vasculature and is expressed in perivascular cells such 
as pericytes, vascular smooth muscle cells, fibroblasts and 
tumor cells, whereas ANG-2 is mainly released by endothelial 
cells only at the sites of vascular remodeling. Both ANG-1 
and ANG-2 are ligands of the Tie2 tyrosine kinase receptor 
presenting similar affinities but antagonistic effects. The 
binding of ANG-1 triggers a signal that finally induces 
vessel maturation and stabilizes tumor vasculature. However, 
ANG-2 competes with ANG-1 for Tie2 binding, causing 
vessel regression in the absence of angiogenic factors, such 
as VEGF, whereas it promotes angiogenesis in the presence 
of VEGF (9,10,37,38). Thus, the ratio of ANG-1 to ANG-2 is 
critical in balancing Tie2 signaling pathways and in regulating 
vascular homeostasis. Angiopoietins seem to act in a 
complementary and coordinated manner with VEGF, playing 
a later role in vascular development. 
Melatonin exerts oncostatic effects through different 
biological mechanisms (39-41). The first description of the 
antiangiogenic properties of melatonin came from a clinical 
study showing a decline in serum levels of VEGF in cancer 
patients treated with this indoleamine (42). More recently it 
has been demonstrated that melatonin exerts antiangiogenic 
actions mainly through its inhibitory actions on VEGF expres-
sion and protein levels (28,29,43,44). The aim of the present 
study was to study whether melatonin may modulate in a 
coordinated action the production of ANG-1 and ANG-2, their 
cognate Tie2 receptor and VEGF in co-cultures of human 
endothelial and breast cancer cells.
Figure 4. Effects of melatonin (1 mM) on ANG-1, ANG-2, Tie2 and VEGF 
mRNA expression in HUVEC co-culture with MCF-7 cells. HUVECs were 
plated (50x104/well) on the bottom wells in VCBM supplemented with 2% 
FBS and incubated overnight. Then, MCF-7 (40x104) cells were seeded on 
the permeable membrane (0.45 µm) of the tissue-culture inserts in dMEM 
supplemented with 10% FBS for 24 h. Media were then replaced with VCBM 
supplemented with 2% FBS containing melatonin (1 mM) or vehicle (eth-
anol) for 4 h. Total mRNA was isolated from cells and reverse transcribed. 
cDNA was subjected to RT-PCR using specific primers for ANG-1, ANG-2, 
Tie2, VEGF or s14. data are expressed as the percentage of the control group, 
cultures of only HUVECs (mean ± SEM). aP<0.05 vs. HUVEC; bP<0.001 
vs. HUVEC; cP<0.05 vs. HUVEC + MCF-7; dP<0.001 vs. HUVEC + MCF-7.
Figure 5. Effects of melatonin (1 mM) on ANG-1, ANG-2, Tie2 and VEGF 
mRNA expression in MCF-7 co-culture with HUVECs. MCF-7 cells were 
plated (80x104/well) on the bottom wells in dMEM supplemented with 10% 
FBS and incubated overnight. Then, HUVECs (30x104) were seeded on 
the permeable membrane (0.45 µm) of the tissue-culture inserts in VCBM 
supplemented with 2% FBS for 24 h. Media were then replaced with VCBM 
supplemented with 2% FBS containing melatonin (1 mM) or vehicle (eth-
anol) for 4 h. Total mRNA was isolated from cells and reverse transcribed. 
cDNA was subjected to RT-PCR using specific primers for ANG-1, ANG-2, 
VEGF, Tie2 or s14. data are expressed as the percentage of the control group, 
cultures of only MCF-7 cells (mean ± SEM). aP<0.001 vs. HUVEC; bP<0.001 
vs. HUVEC + MCF-7.
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Our data, firstly, demonstrated that human breast cancer 
cells can exert a potent influence on endothelial cells and vice 
versa. The presence of breast cancer cells in the co-cultures 
promoted an increase in HUVEC proliferation as well as an 
upregulation of ANG-1, ANG-2 and VEGF mRNA expression 
in endothelial cells in comparison to the HUVEC monocul-
tures. Additionally, the presence of tumor cells also induced 
the downregulation of Tie2 mRNA expression in endothelial 
cells. This pro-angiogenic response was not observed in 
co-cultures of endothelial and non-malignant breast epithelial 
cells which highlights an important difference in the reciprocal 
interactions between endothelial and malignant and non-
malignant breast epithelial cells. The addition of melatonin 
at pharmacological concentrations (1 mM) to the co-culture 
downregulated ANG-1, ANG-2 and VEGF mRNA expres-
sion in endothelial cells and counteracted the reduction in 
Tie2 mRNA expression induced by the presence of the tumor 
cells. Melatonin shifted the ANG-1/ANG-2 balance in favor 
of ANG-1, since it induced a higher reduction in ANG-2 than 
ANG-1 expression. In addition, the presence of breast cancer 
cells significantly increased the levels of ANG-1, ANG-2 and 
Figure 6. Effects of melatonin (1 mM) on ANG-1, ANG-2, Tie2 and VEGF 
mRNA expression in the HUVEC co-culture with MCF-10A cells. HUVECs 
were plated (50x104/well) on the bottom wells in VCBM supplemented 
with 2% FBS and incubated overnight. Then, MCF-10A (30x104) cells were 
seeded on the permeable membrane (0.45 µm) of the tissue-culture inserts in 
dMEM/F12 supplemented with 5% horse serum, 0.5 µg/ml hydrocortisone, 
20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin and 10 µg/ml 
insulin for 24 h. Media were then replaced with VCBM supplemented with 
2% FBS containing melatonin (1 mM) or vehicle (ethanol) for 4 h. Total 
mRNA was isolated from cells and reverse transcribed. cdNA was subjected 
to RT-PCR using specific primers for ANG-1, ANG-2, VEGF, Tier or s14. 
data are expressed as the percentage of the control group, cultures of only 
HUVECs (mean ± SEM). aP<0.001 vs. other groups.
Figure 7. Effects of estradiol (10 nM) and melatonin (1 mM) on ANG-1, 
ANG-2, VEGF and Tie2 mRNA expression in HUVECs. HUVECs were 
seeded (50x104/plate) into Falcon 6-multiwell plates, in VCBM supplemented 
with 2% FBS for 24 h. Media were then replaced with VCBM supplemented 
with 2% FBS containing melatonin (1 mM) and/or estradiol (10 nM) or 
vehicle (ethanol) for 4 h. Total mRNA was isolated from cells and reverse tran-
scribed. cDNA was subjected to RT-PCR using specific primers for ANG-1, 
ANG-2, VEGF, Tie2 or s14. data are expressed as the percentage of the con-
trol group, cultures of only HUVECs (mean ± SEM). aP<0.001 vs. HUVEC; 
bP<0.001 vs. HUVEC + estradiol 10 nM; cP<0.001 vs. HUVEC + melatonin 
1 mM.
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VEGF in the co-culture media, whereas the addition of 1 mM 
melatonin decreased the concentration of ANG-1, ANG-2 and 
VEGF and counteracted the stimulatory effect triggered by the 
presence of tumoral cells. The greatest melatonin inhibition 
of endothelial cell proliferation was found with melatonin 
at a concentration of 1 mM as previously demonstrated (43). 
The oncostatic effects of melatonin on different cells have 
been related with factors such as the concentration of mela-
tonin in the cultures, the time of exposure to this indolamine 
and the concrete characteristics of the cells studied. In our 
study, only pharmacological concentrations of melatonin 
had an inhibitory effect on HUVEC proliferation. A potent 
inhibitory action of melatonin at nanomolar concentrations 
on human breast cancer cell proliferation has been previ-
ously shown (15,16,41,45). However, melatonin at high doses 
is required to obtain antitumoral effects in other types of 
normal cells and tumor cells (43,46-50). It has been described 
that the melatonin concentration in the cerebrospinal fluid is 
higher than that in blood since melatonin is a highly lipophilic 
molecule which may easily cross the blood-brain barrier (51). 
Additionally, it is known that melatonin can become at least 
one thousand times more concentrated in tumoral and adipose 
tissues of the breast (52). The fact that melatonin achieves high 
concentrations in some tissues may justify why high levels of 
melatonin are necessary to obtain some antitumoral effects of 
this indolamine. Thus, we used this pharmacological concen-
tration of melatonin throughout our experimental study, since 
only this dose of melatonin was effective in inhibiting the 
proliferation of HUVECs.
Our results also demonstrated that the pro-angiogenic 
activity of breast cancer cells, but not non-malignant 
mammary epithelial cells, was significantly enhanced by the 
presence of endothelial cells. The presence of endothelial cells 
upregulated ANG-1, ANG-2, Tie2 and VEGF mRNA expres-
sion in the MCF-7 cells and the addition of melatonin 1 mM 
to the co-culture significantly downregulated ANG-1, ANG-2 
and VEGF mRNA expression and upregulated Tie2 mRNA 
expression in the breast cancer cells. It has been described that 
the angiopoietin-Tie2 system has an autoregulation feedback 
system that modulates the overall activity of the Tie2 system. 
ANG-1, but not ANG-2, downregulates Tie2 mRNA expres-
sion (53). In our co-culture experimental design, melatonin 
downregulated both ANG-1 and ANG-2 mRNA expression. 
The lower levels of ANG-1 may explain the upregulation of 
Tie2 mRNA expression induced by melatonin.
Since it is known that estrogens modulate angiogenesis 
and little information is yet available regarding the influence 
of estrogens on angiopoietins, we also aimed to study the 
effects of estradiol on angiopoietin and VEGF mRNA expres-
sion in endothelial cells with and without melatonin. Estradiol 
(10 nM) increased ANG-1, ANG-2 and VEGF mRNA 
expression and melatonin (1 mM) significantly counteracted 
this effect. Melatonin is well known for its oncostatic effects 
on estrogen-dependent breast tumors mainly by two anti-
estrogenic mechanisms: interfering with estrogen signaling 
pathways at the estrogen receptor level (17,19,20) and regu-
lating both the activity and expression of enzymes involved 
in local estrogen biosynthesis in tumor cells and peritumoral 
fibroblasts (40,41,45). This inhibitory action of melatonin 
counteracting the effect of estrogens on angiopoietin and 
VEGF expression, could be included in the oncostatic actions 
of melatonin interfering at different levels in estrogen signaling 
pathways. There has been increasing evidence that estrogens 
regulate angiopoietin expression; however, the differential 
influence of estrogens on ANG-1 and ANG-2 mRNA expres-
sion varies considerably between studies. In non-reproductive 
rat tissues, estradiol increased ANG-2 mRNA expression 
whereas it reduced ANG-1 mRNA expression (54). There is 
one study reporting an inverse correlation of ANG-1 mRNA 
expression with the level of ERα in breast cancer cell lines (55). 
In our cultures, estradiol stimulated endothelial growth and 
increased ANG-1, ANG-2 and VEGF mRNA expression 
while melatonin decreased ANG-1, ANG-2 and VEGF mRNA 
expression and increased Tie2 mRNA expression. The over-
expression of Tie2 induced by melatonin in endothelial cells 
may lead to an increased vessel stabilization, thereby making 
the vasculature less susceptible to pro-angiogenic factors such 
as VEGF.
Sequential and complementary expression of ANG-1, 
ANG-2 and VEGF has been described as crucial for successful 
angiogenesis. Therefore, any interruption or disturbance in this 
balanced expression may significantly affect the angiogenic 
process. In the presence of VEGF, ANG-2 induces vascular 
sprouting and disrupts the interaction between pericytes 
and endothelial cells, promoting the destabilization of blood 
vessels and then increasing VEGF stimulation. In contrast, 
in the absence of VEGF, ANG-2 works as a suppressor that 
potentiates vessel regression (37). Moreover, systemic expres-
sion of ANG-2 has been described to increase metastasis 
and specific blockade of ANG-2 reduces metastasis develop-
ment (56). In preclinical studies, it was demonstrated that the 
association of ANG-2 blockade with VEGF blockade and 
with cytotoxic drugs produced significantly greater inhibitory 
actions on tumor growth and angiogenesis than any agent 
alone (57). Moreover, inhibition of ANG-2 or VEGF reduced 
tumor growth but the inhibition of both together slowed tumor 
growth even more and decreased the number of endothelial 
sprouts to a degree greater than either inhibitor alone (58). 
The use of ANG-2 blockers reduced vessel sprouting, while 
anti-VEGF antibodies that work as blockers of VEGF function 
caused vessel regression (58). Thus, high ANG-2 levels may 
interfere with the efficacy of anti-VEGF therapy. In studies with 
mice, the use of a specific anti-ANG-2 monoclonal antibody 
reduced lung metastasis and lung lymph node metastasis from 
a non-small cell carcinoma (59) and decreased metastasis in 
spontaneous breast carcinoma, which may be explained at least 
to a certain degree by reducing the pro-angiogenic action of 
monocytes associated to tumors (59,60). Recent studies suggest 
the benefits of antitumoral treatments that target multiple anti-
angiogenic pathways, by acting on different receptor tyrosine 
kinases, with the purpose of impairing tumor neovasculariza-
tion more efficiently than either inhibitor alone (58). The fact 
that melatonin has complementary actions and coordinates at 
the same time a downregulation of angiopoietins with a reduc-
tion in VEGF could be an effective therapeutic strategy for 
blocking tumor angiogenesis and growth.
The present study was the first to demonstrate the effect of 
melatonin on angiopoietins in human breast cancer and endo-
thelial cells. We found that the presence of breast cancer cells 
increased endothelial cell proliferation and 1 mM melatonin 
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prevented this effect. ANG-1, ANG-2 and VEGF levels in 
co-culture media and mRNA expression were upregulated 
and Tie2 mRNA expression was downregulated in HUVECs 
and MCF-7 cells. Melatonin (1 mM) downregulated ANG-1, 
ANG-2 and VEGF levels in co-culture media and mRNA 
expression in both types of cells and upregulated Tie2 mRNA 
expression in HUVECs. ANG-1, ANG-2, Tie2 and VEGF 
mRNA expression were not modified during HUVEC/
MCF-10A co-culture. Estradiol (10 nM) increased ANG-1, 
ANG-2 and VEGF mRNA expression in HUVECs and mela-
tonin (1 mM) counteracted this effect. Our findings suggest 
that melatonin simultaneously coordinates downregulation 
of angiopoietins with a reduction of VEGF which could be 
an important action for blocking tumor angiogenesis. Further 
experiments are necessary to clarify the mechanisms involved 
in the antiangiogenic action of melatonin.
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